Treatment of Lambert-Eaton myasthenic syndrome with 3,4-diaminopyridi
Phase 2
Completed
- Conditions
- ambert-Eaton myasthenic syndrome
- Registration Number
- JPRN-UMIN000004795
- Lead Sponsor
- Fukushima Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are not able to comprehend the aim of the present study due to brain metastasis or metabolic encephalopathy are excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eurological findings, Barthel Index, compound motor action potentials and waxing rate on nerve conduction studies conducted 1, 2, 4 months after treatment.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 3,4-diaminopyridine's efficacy in Lambert-Eaton myasthenic syndrome (LEMS)?
How does 3,4-diaminopyridine compare to standard-of-care treatments like pyridostigmine in LEMS clinical outcomes?
Are specific biomarkers associated with response prediction to 3,4-diaminopyridine therapy in LEMS patients?
What adverse events are reported with 3,4-diaminopyridine treatment in Lambert-Eaton syndrome trials?
What combination therapies or alternative drugs show promise for Lambert-Eaton myasthenic syndrome alongside 3,4-diaminopyridine?